BRPI0511822A - heterocyclic derivatives for treatment of hyperlipidemia and related disease - Google Patents
heterocyclic derivatives for treatment of hyperlipidemia and related diseaseInfo
- Publication number
- BRPI0511822A BRPI0511822A BRPI0511822-0A BRPI0511822A BRPI0511822A BR PI0511822 A BRPI0511822 A BR PI0511822A BR PI0511822 A BRPI0511822 A BR PI0511822A BR PI0511822 A BRPI0511822 A BR PI0511822A
- Authority
- BR
- Brazil
- Prior art keywords
- hyperlipidemia
- treatment
- related disease
- heterocyclic derivatives
- heterocyclic
- Prior art date
Links
- 208000031226 Hyperlipidaemia Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57822704P | 2004-06-09 | 2004-06-09 | |
| PCT/US2005/020660 WO2005123686A1 (en) | 2004-06-09 | 2005-06-09 | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0511822A true BRPI0511822A (en) | 2007-12-26 |
Family
ID=34981590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0511822-0A BRPI0511822A (en) | 2004-06-09 | 2005-06-09 | heterocyclic derivatives for treatment of hyperlipidemia and related disease |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20060009487A1 (en) |
| EP (1) | EP1753724A1 (en) |
| JP (1) | JP2008502736A (en) |
| KR (1) | KR20070026598A (en) |
| CN (1) | CN1968928A (en) |
| AR (1) | AR049216A1 (en) |
| AU (1) | AU2005255011A1 (en) |
| BR (1) | BRPI0511822A (en) |
| CA (1) | CA2568394A1 (en) |
| IL (1) | IL179210A0 (en) |
| MX (1) | MXJL06000069A (en) |
| NO (1) | NO20070139L (en) |
| PE (1) | PE20050986A1 (en) |
| RU (1) | RU2006145961A (en) |
| TW (1) | TW200602042A (en) |
| UY (1) | UY28953A1 (en) |
| WO (1) | WO2005123686A1 (en) |
| ZA (1) | ZA200700156B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3965319B2 (en) * | 2001-03-08 | 2007-08-29 | ザ ユニヴァーシティ オブ ホンコン | Organometallic light emitting material |
| AR049081A1 (en) * | 2004-06-09 | 2006-06-21 | Avanir Pharmaceuticals | CHOLESTEROL REVERSE TRANSPORTATION MEDIATORS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA |
| EP1847531A4 (en) * | 2005-02-09 | 2009-04-22 | Takeda Pharmaceutical | Pyrazole compound |
| GB0619611D0 (en) * | 2006-10-04 | 2006-11-15 | Ark Therapeutics Ltd | Compounds and their use |
| DE102009036604A1 (en) | 2009-07-30 | 2011-02-03 | Aicuris Gmbh & Co. Kg | Substituted bis-arylpyrazolamides with terminal primary amide functionality and their use |
| BR112012025167B1 (en) | 2010-04-02 | 2024-01-09 | Firmenich Incorporated | SWEET TASTE MODIFIER |
| CA2841012C (en) | 2011-08-12 | 2019-07-30 | Senomyx, Inc. | Sweet flavor modifier |
| CN103497151B (en) * | 2013-10-30 | 2015-07-15 | 山东铂源药业有限公司 | Synthetic method of 4-amidogen-6-methylnicotinicacid |
| WO2016073251A1 (en) | 2014-11-07 | 2016-05-12 | Senomyx, Inc. | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers |
| CN106187887B (en) * | 2016-07-01 | 2018-08-14 | 上海工程技术大学 | The preparation method of 4- oxyquinoline -3- formic acid |
| AU2017313753B2 (en) | 2016-08-16 | 2022-01-27 | The Trustees Of Columbia University In The City Of New York | GABA(A) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma |
| CN108623561B (en) * | 2017-03-24 | 2025-04-01 | 中国海洋大学 | A method for preparing penicillic acid compound |
| CN108456154A (en) * | 2018-04-13 | 2018-08-28 | 昆明理工大学 | A kind of preparation method of N- tertbutyloxycarbonyls alkyl guanidine |
| WO2020150474A1 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| HUE069590T2 (en) * | 2019-01-18 | 2025-03-28 | Astrazeneca Ab | PCSK9 inhibitor 6'-[[(1s,3s)-3-[[5-(difluoromethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-one and methods for its use |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773946A (en) * | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
| US3930024A (en) * | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
| JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| IL64542A0 (en) * | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| JPS60136512A (en) * | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | Remedy and preventive for hyperlipemia |
| DE3423166A1 (en) * | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | ALPHA, OMEGA DICARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| JPH10316641A (en) * | 1997-03-14 | 1998-12-02 | Sankyo Co Ltd | Carboxylic acid derivative |
| AU8334298A (en) * | 1997-07-15 | 1999-02-10 | Novo Nordisk A/S | Nociceptin analogues |
| US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| DE60037818D1 (en) * | 1999-04-01 | 2008-03-06 | Esperion Therapeutics Inc | ETHER COMPOUNDS, COMPOSITIONS AND ITS USE |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| FR2820435B1 (en) * | 2001-02-05 | 2004-02-27 | Genfit S A | METHODS OF IDENTIFYING COMPOUNDS MODULATING THE REVERSE TRANSPORT OF CHOLESTEROL |
| EP1419770A4 (en) * | 2001-08-24 | 2005-08-03 | Shionogi & Co | Apo ai expression accelerating agent |
| US7429593B2 (en) * | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
| CA2522758A1 (en) * | 2003-04-22 | 2004-11-04 | Avanir Pharmaceuticals | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
-
2005
- 2005-06-09 JP JP2007527787A patent/JP2008502736A/en not_active Withdrawn
- 2005-06-09 US US11/149,067 patent/US20060009487A1/en not_active Abandoned
- 2005-06-09 TW TW094118999A patent/TW200602042A/en unknown
- 2005-06-09 EP EP05758578A patent/EP1753724A1/en not_active Withdrawn
- 2005-06-09 KR KR1020067026459A patent/KR20070026598A/en not_active Withdrawn
- 2005-06-09 MX MXJL06000069A patent/MXJL06000069A/en not_active Application Discontinuation
- 2005-06-09 RU RU2006145961/04A patent/RU2006145961A/en not_active Application Discontinuation
- 2005-06-09 AU AU2005255011A patent/AU2005255011A1/en not_active Abandoned
- 2005-06-09 CA CA002568394A patent/CA2568394A1/en not_active Abandoned
- 2005-06-09 UY UY28953A patent/UY28953A1/en not_active Application Discontinuation
- 2005-06-09 AR ARP050102363A patent/AR049216A1/en unknown
- 2005-06-09 PE PE2005000658A patent/PE20050986A1/en not_active Application Discontinuation
- 2005-06-09 BR BRPI0511822-0A patent/BRPI0511822A/en not_active Application Discontinuation
- 2005-06-09 CN CNA2005800191718A patent/CN1968928A/en active Pending
- 2005-06-09 WO PCT/US2005/020660 patent/WO2005123686A1/en not_active Ceased
-
2006
- 2006-11-13 IL IL179210A patent/IL179210A0/en unknown
-
2007
- 2007-01-05 ZA ZA200700156A patent/ZA200700156B/en unknown
- 2007-01-08 NO NO20070139A patent/NO20070139L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20060009487A1 (en) | 2006-01-12 |
| PE20050986A1 (en) | 2006-02-03 |
| KR20070026598A (en) | 2007-03-08 |
| TW200602042A (en) | 2006-01-16 |
| AU2005255011A1 (en) | 2005-12-29 |
| WO2005123686A1 (en) | 2005-12-29 |
| JP2008502736A (en) | 2008-01-31 |
| CA2568394A1 (en) | 2005-12-29 |
| IL179210A0 (en) | 2007-03-08 |
| CN1968928A (en) | 2007-05-23 |
| NO20070139L (en) | 2007-03-08 |
| UY28953A1 (en) | 2006-01-31 |
| ZA200700156B (en) | 2008-05-28 |
| RU2006145961A (en) | 2008-07-20 |
| EP1753724A1 (en) | 2007-02-21 |
| AR049216A1 (en) | 2006-07-05 |
| MXJL06000069A (en) | 2007-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2022001I1 (en) | DERIVATIVE OF UK-2A | |
| HUS1500034I1 (en) | Indolidone derivatives for the treatment or prevention of fibrosis diseases | |
| DK1849773T3 (en) | Piperazine derivatives for the treatment of urinary incontinence and pain | |
| DK2049525T3 (en) | N-laminoheteroaryl) -1H-indole-2-carboxamide derivatives, and their preparation and therapeutic use | |
| CY2014012I2 (en) | ADMINISTRATION OF DIPEPTIDYLOPEPTIDASE INHIBITORS | |
| PL1708991T3 (en) | Sulfonamide derivatives for the treatment of diseases | |
| CY2017048I2 (en) | NEW PHARMACEUTICAL USES OF STAVROSPORINE DERIVATIVES | |
| BRPI0812361A2 (en) | Heteroaryl PIRAZOL DERIVATIVES SUBSTITUTED FOR THE TREATMENT OF ANGIOGENESE DISORDERS AND HYPERPROLIFERATIVE DISEASES | |
| EE200500033A (en) | Treatment of latent tuberculosis | |
| DK1917246T3 (en) | Benzoquinazoline derivatives and their use in the treatment of bone diseases | |
| BRPI0511822A (en) | heterocyclic derivatives for treatment of hyperlipidemia and related disease | |
| DK1793855T4 (en) | PREVENTION AND TREATMENT OF SYNUCLEINOPATIC AND AMYLOIDOGENIC DISEASE | |
| DK1708992T3 (en) | Sulfonamide derivatives for the treatment of diseases | |
| SI3424932T1 (en) | Boronophthalides for therapeutic use | |
| DK1706112T3 (en) | METHODS OF TREATING AN INFLAMMATOR-RELATED DISEASE | |
| HUS1500058I1 (en) | Benzoxazine-containing drug combination for the treatment of respiratory diseases | |
| DK2026880T4 (en) | PHARMACEUTICAL AND COSMETIC USE OF SILICA | |
| DK2007769T3 (en) | Dimers of artemisinin derivatives, their preparation and therapeutic use thereof | |
| BRPI0607198A2 (en) | composition, use of composition diseases treatment method, and pharmaceutical packaging | |
| BRPI0818267A2 (en) | New 1,3-dihydro-5-isobenzofuranocarbonitrile derivatives and their pharmaceutical composition for the treatment of premature ejaculation | |
| DK1968574T3 (en) | Use of benzo-condensed heterocyclic sulfamide derivatives for the treatment of obesity | |
| ATE484279T1 (en) | ISOSORBIDE MONONITRATE DERIVATIVES FOR THE TREATMENT OF INTESTINAL DISEASES | |
| ATE420081T1 (en) | TRIFLUORMETHYLBENZAMIDE DERIVATIVES AND THERAPEUTIC USES THEREOF | |
| CR8618A (en) | NEW DERIVATIVES OF BENCIL (DIENO) -LACTAMAS | |
| DK1828137T3 (en) | 4-Cycloalkyl-substituted tetrahydroquinoline derivatives and their use as drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |